Checchi Capital Advisers LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 1st quarter, HoldingsChannel reports. The firm bought 1,026 shares of the company’s stock, valued at approximately $229,000.
Other institutional investors have also added to or reduced their stakes in the company. Pearl River Capital LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $28,000. Sontag Advisory LLC bought a new position in IDEXX Laboratories during the fourth quarter worth $79,000. Osborn Williams & Donohoe LLC bought a new position in IDEXX Laboratories during the first quarter worth $90,000. Quantamental Technologies LLC bought a new position in IDEXX Laboratories during the fourth quarter worth $92,000. Finally, Manchester Capital Management LLC lifted its stake in IDEXX Laboratories by 58.5% during the first quarter. Manchester Capital Management LLC now owns 450 shares of the company’s stock worth $101,000 after purchasing an additional 166 shares during the last quarter. Institutional investors own 88.58% of the company’s stock.
In other IDEXX Laboratories news, VP Jacqueline Studer sold 2,529 shares of the stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $210.57, for a total value of $532,531.53. Following the sale, the vice president now directly owns 6,918 shares of the company’s stock, valued at $1,456,723.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Jonathan W. Ayers sold 28,000 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $249.02, for a total value of $6,972,560.00. The disclosure for this sale can be found here. Insiders sold 52,150 shares of company stock worth $12,754,596 over the last ninety days. 2.70% of the stock is owned by corporate insiders.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.13. IDEXX Laboratories had a return on equity of 354,783.84% and a net margin of 17.33%. The firm had revenue of $576.06 million for the quarter, compared to analysts’ expectations of $575.04 million. During the same period last year, the business posted $1.01 earnings per share. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. As a group, analysts predict that IDEXX Laboratories, Inc. will post 4.82 EPS for the current fiscal year.
IDXX has been the topic of several research analyst reports. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, April 3rd. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, March 22nd. Canaccord Genuity reduced their price objective on IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating on the stock in a research note on Tuesday, March 26th. Finally, Guggenheim initiated coverage on IDEXX Laboratories in a research note on Thursday. They set a “buy” rating and a $276.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $256.71.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Recommended Story: Understanding Specialty Certificates of Deposit
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.